METiS Therapeutics
METiS Therapeutics, launched with $86 million in Series A financing, focuses on using AI and machine learning to revolutionize drug discovery and delivery, targeting small molecules, biologics, and nucleic acids.
Company Overview
METiS Therapeutics launched with $86 million in Series A financing. The company aims to transform drug discovery and delivery by leveraging advanced technologies such as artificial intelligence, machine learning, and molecular dynamics. Their focus is on developing novel therapeutics in small molecule, biologics, and advanced nucleic acid spaces. METiS utilizes AI and high-throughput in vivo screening to discover unique lipid nanoparticles (LNPs), demonstrating high delivery efficiency and clean safety profiles in murine and non-human primate (NHP) models.
Artificial Intelligence and Machine Learning in Drug Discovery
METiS Therapeutics is building a proprietary predictive AI platform aimed at redefining drug discovery. This platform uses artificial intelligence and machine learning to develop novel therapeutics in the small molecule, biologics, and advanced nucleic acid spaces. The company’s lead programs leverage AI and high-throughput in vivo screening to discover unique lipid nanoparticles (LNPs). These LNPs have shown evidence of high delivery efficiency and clean safety profiles in preclinical studies involving murine and non-human primate (NHP) models.
Partnerships and Collaborations
METiS Therapeutics is actively seeking partnerships focused on novel AI- and ML-developed nanoparticles. The company has entered into several key partnerships, including a license agreement with Evopoint Biosciences announced on January 6, 2023, and a Pan-RAF Inhibitor License Agreement with Voronoi on September 13, 2022. Additionally, METiS joined the Roche Accelerator on May 18, 2022, further emphasizing its collaborative approach in advancing its proprietary technologies and therapeutic programs.
Advanced Delivery Systems
One of METiS Therapeutics' core strengths lies in creating robust and targeted delivery systems for small molecules, RNA, and gene therapies. The company’s proprietary lipid nanoparticles (LNPs) technology is designed to target multiple organ systems efficiently. Preclinical models involving murine and non-human primates have demonstrated high delivery efficiency and clean safety profiles for these LNPs, highlighting their potential for effective therapeutic applications.